期刊文献+

非小细胞肺癌原发灶与转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1的表达差异 被引量:11

Differential expressions of MDR-1,RRM-1,EGFR and ERCC-1 in primary tumors and metastatic lymph nodes of NSCLC patients
在线阅读 下载PDF
导出
摘要 目的研究非小细胞肺癌(NSCLC)原发灶和转移淋巴结中多药耐药蛋白(MDR-1)、核糖核苷酸还原酶M1(RRM-1)、表皮生长因子受体(EGFR)、错配切除修复蛋白1(ERCC-1)表达的差异,并分析这些表达差异性与临床病理类型的关系。方法采用免疫组织化学染色观察46例NSCLC原发灶及转移淋巴结中MDR-1、RRM-1、EGFR、ERCC-1蛋白的表达情况,用Wilcoxon秩和检验来比较原发灶和淋巴结转移灶表达是否存在差异,用Fisher检验分析差异性是否与病理类型相关。结果 46例各种病理类型的NSCLC,原发病灶与转移淋巴结均存在MDR-1、RRM-1、EGFR、ERCC-1表达,其中ECRR-1的表达差异在腺癌中具有统计学意义(P=0.026),而MDR-1,RRM-1,EGFR的差异性在各病理类型无统计学意义(P>0.05)。结论 MDR-1、RRM-1、EGFR、ERCC-1在NSCLC的原发病灶和转移淋巴结中均表达,但只有ERCC-1在肺腺癌原发灶与转移淋巴结的表达具有明显差异。 Objective To investigate the differential expressions of multidrug resistance protein 1 ( MDR-1 ), ribonucleoti- de reductase MI (RRM-1), epidermal growth factor receptor( EGFR), excision repair cross-complementation group 1 ( ER-CC-1 ) in primary tumors and metastatic lymph nodes of patients with non-small cell lung cancer (NSCLC), and analyze the relationgship between the differential expressions and pathological types of NSCLC. Metheds The expressions of MDR-1, RRM-1, EGFR and ERCC-1 were detected by immunohistochemistry in primary tumors and metastatic lymph nodes of 46 cases NSCLC patients. WUcoxon signed ranks test was used to compare the differences in the expressions of these four molecular markers in primary lesions and metastatic lymph nodes. Fisher's exact test was used to analyze the relationgship between differential expressions and pathological types of NSCLC. Restdts The expressions of MDR-1, RRM-1, EGFR, ERCC-1 were observed in a variety of pathological types of NSCLC. The expression of ERCC-1 was signinifcantly different between primary tumors and metastatic lymph nodes for lung adenocarcinoma (P = 0.026). But the expressions of MDR-1, RRM-1, EGFR were not signinifcantly different between primary tumors and metastatic lymph nodes for all pathological types of NSCLC (P〉0.05). Conclusion The expression of MDR-1, RRM-1, EGFR, ERCC-1 of primary tumors and metastatic lymph nodes is found in all NSCLC. The expression of ERCC-1 is signinifcantly different in primary tumors from in metastatic lymph nodes of lung adenocarcinoma.
出处 《细胞与分子免疫学杂志》 CAS CSCD 北大核心 2013年第8期870-873,共4页 Chinese Journal of Cellular and Molecular Immunology
基金 2010~2011年度吴阶平医学基金会癌症靶向治疗研究基金(320.6750.12199)
关键词 非小细胞肺癌 原发肿瘤 转移淋巴结 多药耐药蛋白 核糖核苷酸还原酶M1 表皮生长因子受体 剪切修复交叉互补基因1 non-small cell lung cancer primary neoplasm metastatic neoplasm of lymph node multidrug resistanceprotein 1 ibonucleotide reductase M1 epidermal growth factor receptor excision repair cross-complementinggene 1
作者简介 郭楠楠(1980-),男,辽宁沈阳人,主治医师,硕士研究生Tel:13811563480;E-mail:gnn304@163.com,同为第一作者. Corresponding author,张文,E-mail:zw304@yahoo.cn
  • 相关文献

参考文献15

  • 1Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012 [J] . CACancer J Clin, 2012, 62(1) : 10-29.
  • 2樊志明,舒祖功,谭江平.非小细胞肺癌生存分析及预后相关因素研究[J].细胞与分子免疫学杂志,2011,27(6):674-675. 被引量:13
  • 3Sandler A, Gray R,Perry MC,et al. Paclitaxel-carboplatin alone orwith bevacizumab for non-small-cell lung cancer[ J]. N En^ J Med,2006,355(24) : 2542 - 2450.
  • 4秦群,肖希斌,谢兆霞.甲基莲心碱联合mdr-1shRNA对K562/A02细胞mdr-1/P-gp表达的影响[J].中南大学学报(医学版),2010,35(5):445-450. 被引量:4
  • 5Li-Blatter X, Beck A, Seelig A- P-glycoprotein-ATPase modulation:the molecular mechanisms [J]. Biophys J, 2012,102 (6) : 1383 -1393.
  • 6高志强,韩宝惠,沈洁,顾爱琴,钟华.晚期非小细胞肺癌RRM1蛋白表达与吉西他滨联合顺铂化疗疗效的关系[J].中国肺癌杂志,2011,14(4):340-344. 被引量:14
  • 7Lee JJ, Maeng CH, Baek SK, et al. The immunohistochemical over-expression of ribonucleotide reductase regulatory subunit Ml(RRM1) protein is a predictor of shorter survival to gemcitabine-based chemotherapy in advanced non-small cell lung cancer(NSCLC) [J]. Lung Cancer, 2010,70(2) : 205 -210.
  • 8Yamaoka T, Ohmori T. The mechanisms of resistance to EGFR-TKIsand challenges to overcome resistance in EGFR mutant non-small celllung cancer[ J]. Gan To Kagaku Eyoho, 2012, 39(6) : 857 -862.
  • 9Papadaki C, Sfakianaki M, Ioannidis G, et al. ERCC1 and BRAC1mRNA expression levels in the primary tumor could predict the effec-tiveness of the second-line cisplatin-based chemotherapy in pretreatedpatients with metastatic non-small cell lung cancer [ J ]. J ThoracOncol, 2012, 7(4): 663 -671.
  • 10Fromowitz FB, Viola MV, Chao S, et al . ras p21 expression in theprogression of breast cancer[ J] . Hum Pathol, 1987,18( 12) : 1268-1275.

二级参考文献26

共引文献28

同被引文献74

引证文献11

二级引证文献68

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部